AstraZeneca, Oxford aim to develop Omicron-targeted vaccine

Portfolio
AstraZeneca said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine, Reuters reported.
AstraZeneca gyár koronavírus gyógyszer

Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data

, a spokesperson for the company said in a statement, Reuters reported.

Oxford did not immediately respond to a request for comment outside business hours.

The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford, as saying that an updated vaccine could be used to “respond to any new variant more rapidly” than previously believed.

Adenovirus-based vaccines [such as that made by Oxford/AstraZeneca] could in principle be used to respond to any new variant more rapidly than some may previously have realised. [They have] really important advantages, especially where need and logistical challenges are greatest,

he said.

A lab-study last week found that AstraZeneca's antibody cocktail Evusheld retained neutralising activity against the Omicron variant.

Vaccine makers Pfizer/BioNTech, and Moderna also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.

Researchers at Imperial College London published a study last week indicating a booster shot could provide up to 80% protection against the Omicron variant.

The modelling, which involved both AstraZeneca and Pfizer vaccines, showed vaccine effectiveness of between 0% and 20% after two doses, and between 55% and 80% after a booster dose. The study was based on limited information on Omicron.

The Guardian cited Imperial researcher Prof Azra Ghani as saying that: “One remaining uncertainty is how severe the disease caused by the Omicron variant is compared to disease caused by previous variants."

Whilst it may take several weeks to fully understand this, governments will need to put in place plans now to mitigate any potential impact. Our results demonstrate the importance of delivering booster doses as part of the wider public health response.

“Prioritising these boosters to high-risk populations over primary vaccination in younger age groups should be part of this response in countries where dose supply is limited.”

Recent analysis by the UK’s Health Security Agency (UKHSA) indicates that a booster offers significantly improved protection against symptomatic infection from the new variant when compared with just two doses.

Whereas two Covid jabs do not offer strong protection against symptomatic infection from Omicron, those who have received a booster jab remain up to 70% protected.

Cover photo: Getty Images.

 

More in Economy

KSH-gdp-növekedés-kiskereskedelem-gazdasági-növekedés-munkaerőpiac-reálbér-megtakarítás-kiskereskedelmi-forgalom-ipar-virovácz-péter
July 17, 2025 12:47

Major Hungarian companies continue workforce reductions across multiple sectors

Retail and manufacturing particularly affected

DBZOL20250703016
July 17, 2025 12:26

50% ownership in a property qualifies for the Home Start loan, no limits on time and amount - Gulyás

The minister spoke at a Government Press Briefing at an unusual Wednesday afternoon timing

GettyImages-1078127808
July 17, 2025 08:11

Poland officially recalls its ambassador to Hungary

Unprecedented move from the fellow V4 country

gyártás hegesztés
July 16, 2025 12:31

Analysts startled by the slow pace of wage growth in Hungary

Wage growth at a multi-year low

munka worker dolgozó hegesz fizetés bérek
July 16, 2025 11:58

Unemployment quietly rises in Hungary

Self-defined unemployed people show a different number than the official statistics

LATEST NEWS

Detailed search